

Lonza Expands HPAPI Multipurpose Suite for Payload-Linker Manufacturing in Visp (CH)

- Lonza adds further capacity for the manufacturing of antibody-drug conjugate (ADC) payloads
 - Expanded multipurpose suite supports payload-linkers development and manufacturing for these increasingly important targeted therapeutics
-

Basel, Switzerland, 14 September 2022 – Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, today announced the completion of the expansion of its Highly Potent API (HPAPI) multipurpose suite in Visp (CH). The expansion adds development and manufacturing capacity for ADC payloads, supporting the entire development and manufacturing pipeline from feasibility studies to commercial supply.

The expansion underlines the strategic position of ADCs in Lonza's portfolio. Lonza develops and produces all components of these increasingly important therapies, including cytotoxic payloads, antibodies and the required linkers, and this latest investment signals continued momentum for Lonza in ADC development and manufacturing.

The ADC market is expected to grow strongly, driven by the growing demand for novel cancer therapeutics with higher targeting abilities. The recent expansion, extending the capacity of the kilogram-scale HPAPI multipurpose manufacturing suite, is well positioned to support this growth.

The new HPAPI suite enables handling compounds with occupational exposure levels down to 1 ng/m³, with a variety of containment solutions and a flexible setup. Equipment on-site includes reactor sizes from 1 L to 50 L with a temperature range of -80°C to +150°C, isolation and drying equipment, lyophilization and chromatography equipment for the manufacture of payload-linkers.

Giovanna Libralon, Senior Director, Commercial Development, Small Molecules, Lonza, commented: "The new expansion represents a key new asset for payload-linker manufacturing, enabling the production of these highly-potent compounds at scale with high flexibility for the execution of different types of operations. The extended capacity will allow us to respond to a growing global need for these therapies, especially in the oncology field."

Iwan Bertholjotti, Senior Director, Commercial Development and Strategic Marketing - Bioconjugates, Lonza, commented: "Lonza's expanded multipurpose suite enables customers to meet the growing demand for targeted cancer treatments by developing and manufacturing ADC payloads with increased speed, capacity and agility. With this new fully integrated offer in Visp, we simplify the supply chain under one roof: from the production of an antibody to the chemical synthesis of complex payload-linkers and bioconjugation."

The expansion in Visp is supported by a dedicated team of experts who have produced more than 300 cGMP batches and developed 15 payload-linkers and 50 HPAPI programs in the past decade. This expertise is available to support customers in process development, clinical and commercial manufacturing.

Learn about Lonza's ADC payload development and manufacturing capabilities here:

<https://www.lonza.com/small-molecules/drug-substance/adc-payload-product-development>

Learn more about Lonza's Bioconjugation offering here:

<https://www.lonza.com/biologics/bioconjugates>

About Lonza

Lonza is a preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. Our unparalleled breadth of offerings enables our customers to commercialize their discoveries and innovations in the healthcare industry.

Founded in 1897 in the Swiss Alps, today, Lonza operates across five continents. With more than 17,000 full-time employees, we comprise high-performing teams and individual talent who make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 3 billion with a CORE EBITDA of CHF 987 million in H1 2022. Find out more at www.lonza.com.

Follow @Lonza on [LinkedIn](#)

Follow @LonzaGroup on [Twitter](#)

Lonza Contact Details

Victoria Morgan

Head of External Communications

Lonza Group Ltd

Tel +41 61 316 2283

victoria.morgan@lonza.com

Dr. Martina Ribar Hesticová

Associate Director, Science Communications

Lonza Group Ltd

Tel +41 61 316 8982

martina.ribarhesticova@lonza.com

Lyle Wheeler

Investor Relations

Lonza Group Ltd

Tel +41 79 154 9522

lyle.wheeler@lonza.com

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.